Product Images Paroxetine

This text appears to be a description of a medication called paroxetine, which is contained in tablets that come in a bottle of 30. Each tablet has 10 mg of paroxetine. The medication should be stored at a temperature between 20 and 25 degrees Celsius and in a tightly sealed container that is resistant to light. There are additional instructions for pharmacists who dispense the medication. There is also a reference to a medication guide that may be available online.*

This text is a product label for a medicine containing paroxetine, with a strength of 20 mg per tablet. The recommended storage conditions are between 20°C to 25°C (68°F to 77°F). The product should be dispensed in a tightly sealed and light-resistant container. Safety closures should be used when dispensing the product. The usual dosage and medication guide are available on the manufacturer's website. The product is manufactured by Apotex Corp. and comes in a pack of 30 tablets.*

This is the information of a medication known as Paroxetine, specifically the 30mg dosage form. It should be stored within temperatures ranging from 20°C to 25°C (68°F to 77°F). Safety closures must be used when dispensing this product, and it should be stored in a light-resistant container. The dosage instructions can be found in the package insert. The tablets are manufactured by Apotex Ing in Toronto, Canada, and are dispensed with a medication guide.*

This is a description of a medication named Paroxetine in 40 mg tablet form. It should be stored in a temperature range of 20°C to 25°C, but it can withstand excursions from 15°C to 30°C. The tablets should be dispensed in a secure, light-resistant container with a safety closure. Dosage information is available in the package insert. The medication is manufactured by Apotex in Toronto, Ontario, Canada, and is distributed by Apotex Corp. in Weston, Florida. A medication guide is available on the manufacturer's website.*

This is a list of drugs and their corresponding dosages. The text mentions a "fold change" and "80% CI," which may pertain to some sort of statistical analysis. However, without further context, it is difficult to determine the exact meaning or significance of these values.*

This text describes the population with information on renal and hepatic impairment, age, and gender. It also includes PK (pharmacokinetic) measures such as Cmax, AUC, and Crmin, as well as fold change and 90% Cl data. The values appear to be related to dosing, with different doses listed for age and renal impairment severity.*